Download PDF
Horm Metab Res 2022; 54(03): 168-174
DOI: 10.1055/a-1743-2988
Endocrine Care

Serum CYR61 Levels are Associated with Graves’ Ophthalmopathy and Smoking in Patients with Graves’ Disease

Perparim Cerri
1   Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, Malmö, Sweden
,
Bushra Shahida 
1   Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, Malmö, Sweden
,
Mikael Lantz 
1   Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, Malmö, Sweden
2   Department of Diabetes and Endocrinology, Skåne University Hospital, Malmö, Sweden
,
Tereza Planck 
1   Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, Malmö, Sweden
2   Department of Diabetes and Endocrinology, Skåne University Hospital, Malmö, Sweden
› Author Affiliations Funding The study was funded by grants from ALF Region Skåne and SUS fonder.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Smoking is a well-known risk factor for Graves’ ophthalmopathy (GO) in patients suffering from Graves’ disease (GD). Cysteine-rich angiogenic inducer 61 (CYR61), which has multiple physiological functions, has been shown to be associated with GD and GO. In this study, we aimed to investigate the association between smoking and CYR61 concentrations in GD patients with and without GO. Serum CYR61 was measured by ELISA. The association between CYR61 concentration and GO was assessed with binary logistic regression in all patients and in subgroups of smokers and nonsmokers. The Spearman correlation coefficient was used to determine the correlations between CYR61 concentration and clinical parameters. CYR61 levels were significantly higher in GD patients with GO than in patients without GO, in smokers than in nonsmokers and in individuals older than 50 years than in those younger than 50 years. The subgroup of “GO smokers” had the highest CYR61 levels [median (IQR), 119 pg/ml (129.8)], compared with “GO nonsmokers” [84.2 pg/ml (90.8), p=0.04], “no GO smokers” [88.9 pg/ml (109.8), p=0.01] and “no GO nonsmokers” [79.4 pg/ml (129.89), p=0.003]. For each unit increase in CYR61 concentration, the odds of having GO in smokers significantly and independently increased by 1% (OR=1.010; 95% CI: 1.002–1.018, p=0.012). In conclusion, our results indicate that smoking and age increase serum CYR61 levels in patients with GD and GO. The role of CYR61 as a predictor of GO in patients with GD should be evaluated in prospective studies.

Key words

CYR61 - CCN1 - Graves’ disease - Graves’ ophthalmopathy - smoking - immediate early genes


Publication History

Received: 15 October 2021

Accepted after revision: 11 January 2022

Article published online:
11 March 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14,70469 Stuttgart, Germany

 

  • References

  • 1 Bahn RS. Current insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res 2015; 47: 773-778
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Wiersinga WM, Smit T, van der Gaag R. et al. Temporal relationship between onset of Graves’ ophthalmopathy and onset of thyroidal Graves’ disease. J Endocrinol Invest 1988; 11: 615-619
    CrossrefPubMedGoogle Scholar
  • 3 Bahn RS, Dutton CM, Natt N. et al. Thyrotropin receptor expression in Graves’ orbital adipose/connective tissues: potential autoantigen in Graves’ ophthalmopathy. J Clin Endocrinol Metab 1998; 83: 998-1002
    PubMedGoogle Scholar
  • 4 Smith TJ. The putative role of fibroblasts in the pathogenesis of Graves’ disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. Autoimmunity 2003; 36: 409-415
    CrossrefPubMedGoogle Scholar
  • 5 Hagg E, Asplund K. Is endocrine ophthalmopathy related to smoking?. Br Med J (Clin Res Ed) 1987; 295: 634-635
    CrossrefPubMedGoogle Scholar
  • 6 Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf) 2013; 79: 145-151
    CrossrefPubMedGoogle Scholar
  • 7 Traisk F, Tallstedt L, Abraham-Nordling M. et al. Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009; 94: 3700-3707
    CrossrefPubMedGoogle Scholar
  • 8 Prummel MF, Wiersinga WM. Smoking and risk of Graves’ disease. JAMA 1993; 269: 479-482
    CrossrefPubMedGoogle Scholar
  • 9 Eckstein A, Quadbeck B, Mueller G. et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 2003; 87: 773-776
    CrossrefPubMedGoogle Scholar
  • 10 Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002; 12: 855-860
    CrossrefPubMedGoogle Scholar
  • 11 Lantz M, Planck T, Asman P. et al. Increased TRAb and/or low anti-TPO titers at diagnosis of graves’ disease are associated with an increased risk of developing ophthalmopathy after onset. Exp Clin Endocrinol Diabetes 2014; 122: 113-117
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Kireeva ML, Mo FE, Yang GP. et al. Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol 1996; 16: 1326-1334
    CrossrefPubMedGoogle Scholar
  • 13 Yeger H, Perbal B. The CCN family of genes: a perspective on CCN biology and therapeutic potential. J Cell Commun Signal 2007; 1: 159-164
    CrossrefPubMedGoogle Scholar
  • 14 Lau LF. CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci 2011; 68: 3149-3163
    CrossrefPubMedGoogle Scholar
  • 15 Kular L, Pakradouni J, Kitabgi P. et al. The CCN family: a new class of inflammation modulators?. Biochimie 2011; 93: 377-388
    CrossrefPubMedGoogle Scholar
  • 16 Lantz M, Vondrichova T, Parikh H. et al. Overexpression of immediate early genes in active Graves’ ophthalmopathy. J Clin Endocrinol Metab 2005; 90: 4784-4791
    CrossrefPubMedGoogle Scholar
  • 17 Vondrichova T, de Capretz A, Parikh H. et al. COX-2 and SCD, markers of inflammation and adipogenesis, are related to disease activity in Graves’ ophthalmopathy. Thyroid 2007; 17: 511-517
    CrossrefPubMedGoogle Scholar
  • 18 Woo YJ, Seo Y, Kim JJ. et al. Serum CYR61 is associated with disease activity in Graves’ orbitopathy. Ocul Immunol Inflamm 2018; 26: 1094-1100
    CrossrefPubMedGoogle Scholar
  • 19 Planck T, Shahida B, Parikh H. et al. Smoking induces overexpression of immediate early genes in active Graves’ ophthalmopathy. Thyroid 2014; 24: 1524-1532
    CrossrefPubMedGoogle Scholar
  • 20 Planck T, Shahida B, Sjogren M. et al. Association of BTG2, CYR61, ZFP36, and SCD gene polymorphisms with Graves’ disease and ophthalmopathy. Thyroid 2014; 24: 1156-1161
    CrossrefPubMedGoogle Scholar
  • 21 Prummel MF, Bakker A, Wiersinga WM. et al. Multi-center study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first European group on Graves’ orbitopathy experience. Eur J Endocrinol 2003; 148: 491-495
    CrossrefPubMedGoogle Scholar
  • 22 Gerding MN, van der Meer JW, Broenink M. et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 2000; 52: 267-271
    CrossrefPubMedGoogle Scholar
  • 23 Turck N, Eperon S, De Los Angeles Gracia M. et al. Thyroid-associated orbitopathy and biomarkers: where we are and what we can hope for the future. Disease Markers 2018; 7010196
    PubMedGoogle Scholar
  • 24 Lin J, Li N, Chen H. et al. Serum Cyr61 is associated with clinical disease activity and inflammation in patients with systemic lupus erythematosus. Medicine 2015; 94: e834
    CrossrefPubMedGoogle Scholar
  • 25 Fan Y, Yang X, Zhao J. et al. Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis. Arthritis Res Ther 2019; 21: 123
    CrossrefPubMedGoogle Scholar
  • 26 Xie D, Yin D, Wang HJ. et al. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 2004; 10: 2072-2081
    CrossrefPubMedGoogle Scholar
  • 27 Xie D, Nakachi K, Wang H. et al. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001; 61: 8917-8923
    PubMedGoogle Scholar
  • 28 Shi J, Huo R, Li N. et al. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. BMC Cancer 2019; 19: 1140
    CrossrefPubMedGoogle Scholar
  • 29 Zhao J, Zhang C, Liu J. et al. Prognostic significance of serum cysteine-rich protein 61 in patients with acute heart failure. Cell Physiol Biochem 2018; 48: 1177-1187
    CrossrefPubMedGoogle Scholar
  • 30 Liu C, Cao Y, He X. et al. Association of Cyr61-cysteine-rich protein 61 and short-term mortality in patients with acute heart failure and coronary heart disease. Biomark Med 2019; 13: 1589-1597
    CrossrefPubMedGoogle Scholar
  • 31 Deng J, Qian X, Li J. et al. Evaluation of serum cysteine-rich protein 61 levels in patients with coronary artery disease. Biomark Med 2018; 12: 329-339
    CrossrefPubMedGoogle Scholar
  • 32 Song YF, Xu ZB, Zhu XJ. et al. Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer. Clin Transl Oncol 2017; 19: 519-524
    CrossrefPubMedGoogle Scholar
  • 33 Wei J, Yu G, Shao G. et al. CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma. Oncotarget 2016; 7: 31067-31078
    CrossrefPubMedGoogle Scholar
  • 34 Zhao ZS, Li L, Wang HJ. et al. Expression and prognostic significance of CEACAM6, ITGB1, and CYR61 in peripheral blood of patients with gastric cancer. J Surg Oncol 2011; 104: 525-529
    CrossrefPubMedGoogle Scholar
  • 35 Zhou ZQ, Cao WH, Xie JJ. et al. Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma. BMC Cancer 2009; 9: 291
    CrossrefPubMedGoogle Scholar
  • 36 Kok SH, Chang HH, Tsai JY. et al. Expression of Cyr61 (CCN1) in human oral squamous cell carcinoma: An independent marker for poor prognosis. Head Neck 2010; 32: 1665-1673
    CrossrefPubMedGoogle Scholar
  • 37 D’Antonio KB, Toubaji A, Albadine R. et al. Extracellular matrix associated protein CYR61 is linked to prostate cancer development. J Urol 2010; 183: 1604-1610
    CrossrefPubMedGoogle Scholar